CRISPR editing for treating Duchenne muscular dystrophy

Researchers are using CRISPR gene editing to restore function of the mutant protein that causes Duchenne muscular dystrophy, a genetic disease that causes muscle degeneration.

Oct 13, 2021
Natalya Ortolano, PhD

Duchenne muscular dystrophy is a rare genetic disorder that causes muscles to slowly break down over time, leading to symptoms such as difficulty walking. Dysfunction of the muscle stabilizing protein dystrophin is the primary cause of the disease. The biotech company MyoGeneBio uses CRISPR gene editing to restore partial function of dystrophin to minimize symptoms and slow the progression of disease.

Download the infographic: CRISPR editing for treating Duchenne muscular dystrophy

By Natalya Ortolano, PhD
illustrated by Shannon herring
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Latest Issue's Magazine Cover

Latest Issue  

• Volume 17 • Issue 10 • October 2021

October 2021

October 2021 Issue